188 related articles for article (PubMed ID: 34638130)
41. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
42. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
[TBL] [Abstract][Full Text] [Related]
43. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
44. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
45. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
[TBL] [Abstract][Full Text] [Related]
46. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
47. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells.
White NJ; Nacheva E; Asimakopoulos FA; Bloxham D; Paul B; Green AR
Blood; 1994 May; 83(10):2809-16. PubMed ID: 8180377
[TBL] [Abstract][Full Text] [Related]
48. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
49. GAB2 is a novel target of 11q amplification in AML/MDS.
Zatkova A; Schoch C; Speleman F; Poppe B; Mannhalter C; Fonatsch C; Wimmer K
Genes Chromosomes Cancer; 2006 Sep; 45(9):798-807. PubMed ID: 16736498
[TBL] [Abstract][Full Text] [Related]
50. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes.
Drexler HG
Leuk Res; 2000 Feb; 24(2):109-15. PubMed ID: 10654445
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.
Dubourg C; Toutain B; Hélias C; Henry C; Lessard M; Le Gall JY; Le Treut A; Guenet L
Cancer Genet Cytogenet; 2002 Apr; 134(1):33-7. PubMed ID: 11996793
[TBL] [Abstract][Full Text] [Related]
52. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia.
Tamura S; Takemoto Y; Hashimoto-Tamaoki T; Mimura K; Sugahara Y; Senoh J; Furuyama JI; Kakishita E
Int J Oncol; 1998 Jun; 12(6):1259-62. PubMed ID: 9592183
[TBL] [Abstract][Full Text] [Related]
53. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
55. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
56. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
57. Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.
Klampfl T; Milosevic JD; Puda A; Schönegger A; Bagienski K; Berg T; Harutyunyan AS; Gisslinger B; Rumi E; Malcovati L; Pietra D; Elena C; Della Porta MG; Pieri L; Guglielmelli P; Bock C; Doubek M; Dvorakova D; Suvajdzic N; Tomin D; Tosic N; Racil Z; Steurer M; Pavlovic S; Vannucchi AM; Cazzola M; Gisslinger H; Kralovics R
PLoS One; 2013; 8(10):e77819. PubMed ID: 24147083
[TBL] [Abstract][Full Text] [Related]
58. Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review.
Panani AD; Pappa V; Papageorgiou S; Stamatelli F; Raptis SA
Ann Hematol; 2004 Mar; 83(3):153-5. PubMed ID: 15064863
[TBL] [Abstract][Full Text] [Related]
59. Molecular mechanisms of myelodysplastic syndrome.
Hirai H
Jpn J Clin Oncol; 2003 Apr; 33(4):153-60. PubMed ID: 12810828
[TBL] [Abstract][Full Text] [Related]
60. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
